Body mass index, but not vitamin D status, is associated with brain volume change in MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 14, 2018
- Accepted in final form August 27, 2018
- First Published November 14, 2018.
Article Versions
- Previous version (November 14, 2018 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Ellen M. Mowry, MD, MCR,
- Christina J. Azevedo, MD, MPH,
- Charles E. McCulloch, PhD,
- Darin T. Okuda, MD,
- Robin R. Lincoln, BS,
- Emmanuelle Waubant, MD, PhD,
- Stephen L. Hauser, MD and
- Daniel Pelletier, MD
- Ellen M. Mowry, MD, MCR,
DSMB for liothyronine study (non-profit)
NONE
NONE
Editorial board, Frontiers in Neuroepidemiomology, 2017- present
NONE
UptoDate chapter editor (Pathogenesis and epidemiology of multiple sclerosis)
NONE
NONE
NONE
NONE
NONE
(1)Free glatiramer acetate for a clinical trial from Teva Neuroscience. (2)Research funding paid to my institution from Biogen Idec and Genzyme (for investigator-initiated studies). (3) Site PI of two trials sponsored by Sun Pharma and Biogen
(1)Department of Defense
NONE
1. National Multiple Sclerosis Society RG4407A22. 2. National Multiple Sclerosis Society JF2164A7 3. Patient- Centered Outcomes Research Institute (PCORI)
NONE
NONE
NONE
NONE
NONE
NONE
- Christina J. Azevedo, MD, MPH,
In the past two years, I have received honoraria for serving on scientific advisory boards for: (1) Genentech (2) Guerbet, L.L.C. (3) Biogen-Idec (4) Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am supported by a 3-year Institutional Career Development Award through the Southern California Clinical and Translational Science Institute (Grant # UL1TR001855 from the National Center for Advancing Translational Science) My role is an Institutional Scholar.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Charles E. McCulloch, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH, KL2 RR024130, Biostatistics mentor, 2010-2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Darin T. Okuda, MD,
DSMB Chair (Osmotica)
NONE
1. Acorda, travel and speaker fees 2. Genzyme, travel and speaker fees 3. Teva, travel and speaker fees
NONE
NONE
NONE
NONE
(1). Celgene (2). Bayer (3). EMD Serono (4). Genzyme (5). Novartis
(1). Acorda Therapeutics (2). Genzyme (3). TEVA
NONE
NONE
Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Robin R. Lincoln, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Emmanuelle Waubant, MD, PhD,
I volunteer on a Novartis advisory board (pharmaceutical company)for a clinical trial
NONE
AAN has covered my travel and provided an honorarium in 2018 for my talk in Frontiers in Neurosciences
-Section editor for Annals of Clinical and Translational Neurology since 2017 -Co-chief Editor for MSARD since 2016
NONE
Demyelinating disorders of the central nervous system in childhood. Cambridge University. 2011 Pediatric MS and related disorders. 2017
NONE
NONE
NONE
NONE
NONE
I am site PI for trials of ocrelizumab in PPMS (Roche, company), and fingolimod in pediatric MS (Novartis, company)
I am co-PI for a trial sponsored by PCORI
NONE
I am supported by the National MS Society RG4861A3/1 (PI Waubant), and the Race to Erase MS (medical director)
NONE
NONE
NONE
NONE
NONE
NONE
- Stephen L. Hauser, MD and
Dr. Stephen L. Hauser serves on the scientific advisory boards for Bionure,Annexon,Alector, Symbiotix, and Molecular Stethoscope. He serves on the board of trustees for Neurona.
NONE
NONE
NONE
NONE
(1) Harrison's Principles of Internal Medicine, McGraw-Hill Publishers, 1994-present
(1)University of California, San Francisco, Professor of Neurology, Director of the Weill Institute for Neurosciences.
NONE
NONE
NONE
NONE
NONE
NIH Funding, Grant # R01 NS092835 NIH Funding, Grant # R01 NS026799 NIH Funding, Grant # R01 NS099240
NONE
National Multiple Sclerosis Society (NMSS), Grant # RR 2005-A-13 (G-1510-06785); RG-1611-26299 Conrad Hilton Foundation, 16850
(1)Bionure, Dr. Hauser received stock options from Bionure, all of which were transferred to his institution (UCSF) (2) Annexon, Dr. Hauser received stock options from Annexon, all of which were transferred to his institution (UCSF) (3) Symbiotix, Dr. Hauser received stock options from Symbiotix, all of which were transferred to his institution (UCSF)
NONE
NONE
NONE
NONE
NONE
- Daniel Pelletier, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Pelletier received consulting fees from Biogen, Sanofi-Genzyme, Novartis, Hoffmann LaRoche, and Actelion.
NONE
NONE
NONE
NONE
NONE
NONE
National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (E.M.M.), Johns Hopkins University, Baltimore, MD; Department of Neurology (C.A., D.P.), University of Southern California, Los Angeles; Department of Epidemiology and Biostatistics (C.E.M.) and MS Center (R.R.L., E.W., S.L.H.), Department of Neurology, University of California, San Francisco; and Department of Neurology (D.T.O.), University of Texas Southwestern, Dallas.
- Correspondence
Dr. Mowry emowry1{at}jhmi.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.